novo semaglutide alzheimer's π¨ Breaking: Oral Did Not Slow Progression in Phase 3 Trials - Novo reports 2 trial failures
Description
Recent study found a troubling link between the use of semaglutide (marketed as Ozempic or Wegovy) and an increased risk of developing a potentially blinding eye condition known as NAION
doi: 10.1155/2024/7310510
Theyre also in the brainstem, where they help regulate autonomic control of the heart
Learn how expert guidance and lifestyle support optimize your results.
Experienced Dallas commercial litigation attorney
Functional Wellness Minneapolis Anti-aging and Wellness Unlock the secret to ageless beauty
